COPENHAGEN, Denmark, September 09, 2025--(BUSINESS WIRE)--Neurescue ApS today announced CE Mark approval for the NEURESCUE ® device, the first and only medical device approved to treat non-shockable ...

Research indicates that non-shockable cardiac arrest is associated with higher mortality rates compared to cardiac arrest cases wherein shockable rhythms such as ventricular fibrillation or pulseless ...

The FDA granted Neurescue a "two-fer" on its intelligent balloon catheter for aortic occlusion with 510(k) clearance for emergency control of hemorrhage and investigational device exemption for use in ...

Heart disease is one of the leading causes of death in the world, with around half of these being the result of sudden cardiac death. Treatment for this usually consists of chest compressions and ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Neurescue, a medical device company developing innovative cardiovascular solutions to improve the outcomes for emergency patients, today announced that the U.S.

LONG BEACH, Calif., May 12, 2022 /PRNewswire/ -- The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only national site to offer and enroll patients in the ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Neurescue, a clinical-stage medical device company bringing to market the world’s first computer-aided balloon catheter for aortic occlusion, today announced that ...

Neurescue ApS today announced CE Mark approval for the NEURESCUE ® device, the first and only medical device approved to treat non-shockable cardiac arrest. Granted by TÜV SÜD after an expedited ...

Device is FDA IDE approved to start a clinical study in the U.S. to investigate a novel cardiac arrest treatment indication Neurescue, a medical device company developing innovative cardiovascular ...

A life-saving breakthrough for the 81% of cardiac arrest patients who are ineligible for defibrillation Neurescue ApS today announced CE Mark approval for the NEURESCUE device, the first and only ...